TP53 and osteoarthritis: Aside from considerations of dose, pharmacokinetics, and schedule of administration as potential problem points, and assuming that the MDM2-P53 molecular interaction is similar enough in dog and human to support UBX0101 binding, a hypothetical case can be made for interposing a companion canine osteoarthritis study prior to the second phase two study (or earlier) as suggested in Figure 1.